Back in October, Sanofi spooked investors when it unveiled its strategy to increase R&D investment as its transitions to a pure play biopharma – the prospect of lower profits wiping €20bn ($21bn) off its market value. (Also see "Sanofi Stock Slides On Lower Profit Forecast And Consumer Health Spinoff Plan" - Scrip, 27 October, 2023.)
Key Takeaways
-
Sanofi’s new strategy means more money for R&D – but investors want to be sure these bets will pay off
-
Its new R&D head wants to see money diverted away from areas like oncology and into immunology, its strongest therapy class
The Paris-headquartered company’s shares have still not recovered from that news, but at an R&D day on 7 December, its CEO and new research head sought to further explain its plans to create a new generation of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?